Core Insights - The winter worm and summer grass industry is undergoing a transformation due to the application of modern technology, addressing challenges such as resource scarcity and increasing market demand [4][5][6] Industry Overview - The market for winter worm and summer grass in China has reached over 70 billion yuan and is moving towards a trillion yuan market size, driven by rising health awareness among the population [4] - Winter worm and summer grass is classified as a national second-level protected species due to overharvesting and environmental changes, leading to a significant decline in its natural production [4][5] Company Developments - Dongyangguang Group has established the world's first and largest ecological breeding industrial base for winter worm and summer grass, investing over 4 billion yuan and employing a research team of more than 260 people since 2007 [3][4][5] - The company has developed a unique ecological breeding path for winter worm and summer grass, achieving a stable annual production of over 60 tons, with products that closely resemble wild varieties in terms of quality and nutritional content [5][6] Product Innovation - Dongyangguang has introduced fresh winter worm and summer grass products that retain higher levels of active ingredients, utilizing advanced preservation techniques to enhance consumer experience [6][7] - The company has developed a range of products including fresh, freeze-dried, and concentrated forms of winter worm and summer grass, catering to various consumer needs and preferences [10] Global Expansion Strategy - Dongyangguang is focusing on global market expansion, aiming to establish a strong international brand presence for winter worm and summer grass while promoting Chinese health culture [11][15] - The company has initiated partnerships and sponsorships in high-profile events and media to enhance brand visibility and consumer engagement [13][15]

Core Viewpoint - Dongyangguang Yangtze Pharmaceutical is progressing towards a merger with Dongyangguang Pharmaceutical, with two out of three prerequisite conditions met for the final merger [1] - The company has submitted a listing application to the Hong Kong Stock Exchange, indicating a clear path for its upcoming market entry [1] - Investor confidence is reflected in the significant increase in shareholding by Hong Kong Stock Connect funds, rising from 11.99% to 33.93% since September 2022, with a market value exceeding 3 billion HKD [1] Group 1: Merger and Market Position - Dongyangguang Pharmaceutical's upcoming listing is seen as a high-value investment opportunity in the biopharmaceutical sector, attracting significant interest from investors [4] - The company has established itself as a leading innovative pharmaceutical enterprise in China, focusing on differentiated innovation to meet clinical needs [5][8] Group 2: Research and Development - Dongyangguang Pharmaceutical has a robust R&D platform with over 1,100 professionals, covering the entire drug development lifecycle [5][6] - The company currently has 150 drugs on the market and over 100 in development, including 49 first-class innovative drugs [6] - The company has filed 2,446 invention patents, with 1,401 granted, ranking first among domestic pharmaceutical companies in patent filings from 2014 to 2023 [6] Group 3: Financial Performance - The company has shown significant revenue growth, with projected revenues of 38.14 billion CNY, 63.86 billion CNY, and 40.19 billion CNY from 2022 to 2024, maintaining a gross margin above 76% [10] - In 2023, the company achieved a net profit of 1.014 billion CNY, with a net profit margin of 15.9% [10] - R&D investment is expected to reach 493 million CNY in 2024, a year-on-year increase of 156.62% [10] Group 4: Product Pipeline and Market Strategy - The company is focusing on three key therapeutic areas: infections, chronic diseases, and oncology, with a diverse product portfolio [10][11] - Dongyangguang Pharmaceutical has established a strong sales network covering 32 provincial regions in China and is expanding into international markets [12] - The company has secured significant licensing agreements, including a $938 million deal with Apollo Therapeutics for its FGF21/GLP-1 dual-specific fusion protein [8][9]

Group 1 - China Biopharmaceutical announced a significant outbound licensing deal as part of its strategic goals for the year, aiming to enhance international revenue and initiate a second growth curve [1] - The company has multiple assets with outbound licensing potential, including PDE3/4, HER2 bispecific antibodies, HER2 ADC, FGF21, EGFR/cMET ADC, fourth-generation EGFR, and early-stage projects like oral GLP-1 and PDE4b, which have shown high commercial value in the global pharmaceutical market [1] Group 2 - Dongyang Sunshine Pharmaceutical submitted its IPO application to the Hong Kong Stock Exchange, with CICC as the sole sponsor, focusing on infection, chronic diseases, and oncology treatment areas [2] - The company has a product matrix of 150 approved drugs across various countries, with 48 sold in China and 23 in overseas markets, indicating potential for accelerated international expansion [2] Group 3 - Heyu Pharmaceutical's new drug application for pimicotinib, a selective small molecule inhibitor for TGCT, has been accepted by the NMPA, marking the company's first project entering the NDA approval process [3] - Pimicotinib has demonstrated good clinical efficacy, safety, and tolerability in multiple clinical trials, and its approval could fill a gap in the treatment of TGCT, enhancing the company's innovative competitiveness [3] Group 4 - Tianxing Medical's IPO application on the Sci-Tech Innovation Board has been terminated due to the withdrawal of its sponsor, despite having a complete matrix of 47 approved sports medicine products, including 11 that are the first of their kind in China [4] - The termination of the IPO reflects potential challenges in research, commercialization, and the overall difficulties faced by innovative medical device companies in the listing process [4]

Core Viewpoint - Dongyang Sunshine Pharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CICC as the sole sponsor [1] Group 1: Company Overview - Dongyang Sunshine Pharmaceutical is a comprehensive pharmaceutical company focused on the research, production, and commercialization of drugs, particularly in the fields of infection, chronic diseases, and oncology [3] - The company has developed a diverse and robust product portfolio, with 150 approved drugs across various countries and regions, including China, the United States, and Europe [5] Group 2: Financial Performance - For the fiscal years ending December 31, 2022, 2023, and 2024, Dongyang Sunshine's revenue from anti-infection drugs was approximately RMB 3.242 billion, RMB 5.746 billion, and RMB 2.798 billion, accounting for 85.0%, 90.0%, and 69.6% of total revenue, respectively [3] - The revenue from chronic disease treatment drugs for the same periods was RMB 517 million, RMB 581 million, and RMB 1.068 billion, representing 13.6%, 9.1%, and 26.6% of total revenue, respectively [3] - The company's total revenue for the fiscal years 2022, 2023, and 2024 was approximately RMB 3.814 billion, RMB 6.386 billion, and RMB 4.019 billion, with gross profits of RMB 2.922 billion, RMB 5.077 billion, and RMB 3.059 billion, respectively [6] Group 3: Market Presence - As of June 4, 2025, Dongyang Sunshine sold 48 drugs in China and 23 drugs in overseas markets, with revenue from China being RMB 3.753 billion, RMB 6.336 billion, and RMB 3.881 billion for the years 2022, 2023, and 2024, respectively, accounting for 98.4%, 99.2%, and 96.6% of total revenue [4] - The company has engaged in research and development collaborations with overseas partners, generating overseas revenue of RMB 60.4 million, RMB 49.7 million, and RMB 138.4 million for the same periods, representing 1.6%, 0.8%, and 3.4% of total revenue, respectively [4]

Group 1 - Guangdong Dongyangguang Pharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange [1] - The exclusive sponsor for the listing is China International Capital Corporation (CICC) [1]

东阳光药业是一家综合性制药公司，主要从事药物的研发、生产和商业化。公司战略性地专注于感染、 慢病及肿瘤等治疗领域，在中国生产药物并主要在中国销售药品。截至最后实际可行日期，公司在中国 销售48款药物，并在海外市场销售23款药物。 6月11日，广东东阳光药业股份有限公司（以下简称"东阳光药业"）向港交所提交上市申请书，独家保 荐人为中国国际金融香港证券有限公司。 然而，公司目前面临两大主要风险：首先，公司收入和盈利能力过度依赖抗流感药物可威®（磷酸奥司 他韦）。2022-2024年，磷酸奥司他韦的销售额分别占公司总收入的81.2%、86.9%和64.2%。其次，可 威®的销售受流感发病率影响显著且具有明显的季节性，导致公司收入波动较大。例如，2024年由于中 国流感发病率下降，公司可威®销售额较2023年大幅下滑。 公司拥有完善的研发平台和生产体系。公司拥有超过1,100名研发人员，研发平台覆盖化学药及生物药 完整生命周期。公司的生产设施已获得中国、美国和欧洲的GMP认证，拥有四处生产基地，总建筑面 积约301,160平方米，设有16个主要生产车间。公司在中国抗病毒药物市场占据领先地位，以销售收入 计过去五年在 ...

Core Viewpoint - Dongyangguang Changjiang Pharmaceutical has shown significant stock performance with a year-to-date increase of 36.61%, outperforming the Hang Seng Index by 18.61% despite a substantial decline in revenue and profit [1][2]. Financial Performance - As of December 31, 2024, Dongyangguang Changjiang Pharmaceutical reported total revenue of 3.724 billion yuan, a year-on-year decrease of 40.84% - The net profit attributable to shareholders was 483 million yuan, down 75.78% year-on-year - The gross profit margin stood at 75.03%, and the debt-to-asset ratio was 31.55% [1]. Market Position and Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 4.17 times, with a median of 5.82 times - Dongyangguang Changjiang Pharmaceutical has a P/E ratio of 22.05 times, ranking 51st in the industry [2]. Company Background - Dongyangguang Changjiang Pharmaceutical, established in August 2001, focuses on the development, production, and sales of products for antiviral, endocrine and metabolic diseases, and cardiovascular diseases - The company has a distribution network for 33 pharmaceutical products in China [2]. Product Development and Market Strategy - The company is the sole manufacturer of oseltamivir phosphate granules in China, solidifying its position in the antiviral market - Dongyangguang Changjiang Pharmaceutical plans to expand its product offerings into other therapeutic areas, including gastrointestinal diseases, and has a strong pipeline of future products, particularly in the insulin series [3][4]. Research and Development Capabilities - The company has access to research and development from its parent company, which is a leading drug research institution in China with over 1,200 researchers - The management team is experienced and holds professional qualifications, enhancing the company's ability to implement its strategic plans successfully [4].

Investment Rating - The investment rating for the chemical raw materials industry is "Positive" (maintained) [1] Core Viewpoints - The refrigerant market is experiencing an upward trend, with continuous validation of industrial logic, suggesting active investment opportunities [4] - The fluorochemical industry chain has entered a long-term prosperity cycle, with significant growth potential across various segments, including refrigerants and high-end fluorinated materials [20] Summary by Sections 1. Fluorochemical Market Overview - The fluorochemical index increased by 4.23% during the week of June 2 to June 6, outperforming the Shanghai Composite Index by 3.10% [5][22] - The average price of 97% wet fluorite was 3,387 CNY/ton, down 3.09% week-on-week, while the average for June was 3,416 CNY/ton, down 9.85% year-on-year [6][29] 2. Refrigerant Market Trends - As of June 6, 2025, the prices for various refrigerants are as follows: R32 at 51,000 CNY/ton, R125 at 45,500 CNY/ton, R134a at 48,500 CNY/ton, R410a at 48,500 CNY/ton, and R22 at 36,000 CNY/ton, with most prices stable compared to the previous week [7][18] - The market is seeing a significant increase in demand for refrigerants post-Duanwu Festival, with prices expected to rise further in June [19] 3. Recommended Stocks - Recommended stocks include Jinshi Resources, Juhua Co., Sanmei Co., and Haohua Technology, with other beneficiaries being Dongyangguang, Yonghe Co., Dongyue Group, and Xinzhoubang [9][20]

管理人名称：宁波勇诚资产管理有限公司 证券代码：600673 证券简称：东阳光 编号：临 2025-39 号 债券代码：242444 债券简称：25 东科 01 广东东阳光科技控股股份有限公司 关于参与设立创业投资基金的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 对外投资概述 广东东阳光科技控股股份有限公司（以下简称"公司"或"东阳光"）与关 联方深圳东阳光科技创业投资有限公司（以下简称"东阳光创投"）、非关联方宁 波城投赋甬股权投资合伙企业（有限合伙）（以下简称"宁波城投"）、宁波勇诚 资产管理有限公司（以下简称"宁波勇诚"）、禤慧宁、王滨、梁相炳共同出资设 立宁波勇诚东阳光创业投资基金合伙企业（有限合伙）（以下简称"合伙企业" 或"基金"），该合伙企业认缴出资额 10,000 万元人民币，其中公司作为有限合 伙人以自有资金方式认缴出资 4,900 万元人民币，占合伙企业认缴出资总额的 www.sse.com.cn 上披露的《东阳光关于参与设立创业投资基金暨关联交易的公 告》（临 2024-81 号）。 ...

二、 投资进展情况 近日，公司收到基金管理人宁波勇诚的通知，基金已根据《中华人民共和国 证券投资基金法》及《私募投资基金监督管理暂行办法》等法律法规的要求在中 国证券投资基金业协会完成了基金备案手续，并取得《私募投资基金备案证明》， 具体备案信息如下： 基金名称：宁波勇诚东阳光创业投资基金合伙企业（有限合伙） | 证券代码：600673 | 证券简称：东阳光 | | 编号：临 | 2025-39 号 | | --- | --- | --- | --- | --- | | 债券代码：242444 | 债券简称：25 | 东科 01 | | | 广东东阳光科技控股股份有限公司 关于参与设立创业投资基金的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 对外投资概述 广东东阳光科技控股股份有限公司（以下简称"公司"或"东阳光"）与关 联方深圳东阳光科技创业投资有限公司（以下简称"东阳光创投"）、非关联方宁 波城投赋甬股权投资合伙企业（有限合伙）（以下简称"宁波城投"）、宁波勇诚 资产管理有限公司（以下简称"宁波勇诚"） ...